Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseases

被引：0
|
作者：
Kurti, Z. [1 ]
Vegh, Z. [1 ]
Rutka, M. [2 ]
Gonczi, L. [1 ]
Farkas, K. [2 ]
Gecse, K. [1 ]
Golovics, P. A. [1 ]
Szalay, B. [3 ]
Molnar, T. [2 ]
Lakatos, P. [1 ]
机构：
[1] Semmelweis Univ, Dept Med 1, H-1085 Budapest, Hungary
[2] Univ Szeged, Dept Med 1, Szeged, Hungary
[3] Semmelweis Univ, Dept Lab Med, H-1085 Budapest, Hungary
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P308
引用
收藏
页码：S249 / S249
页数：1
相关论文
共 50 条
  • [1] Predictors of Loss of Response to Adalimumab Therapy; the Importance of Therapeutic Drug Monitoring in Inflammatory Bowel Diseases
    Kurti, Zsuzsanna
    Vegh, Zsuzsanna
    Golovics, Petra A.
    Gecse, Krisztina
    Gonczi, Lorant
    Rutka, Mariann
    Farkas, Klaudia
    Molnar, Tamas
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2016, 150 (04) : S423 - S423
  • [2] Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
    Lorant Gonczi
    Zsuzsanna Kurti
    Mariann Rutka
    Zsuzsanna Vegh
    Klaudia Farkas
    Barbara D. Lovasz
    Petra A. Golovics
    Krisztina B. Gecse
    Balazs Szalay
    Tamas Molnar
    Peter L. Lakatos
    BMC Gastroenterology, 17
  • [3] Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
    Gonczi, Lorant
    Kurti, Zsuzsanna
    Rutka, Mariann
    Vegh, Zsuzsanna
    Farkas, Klaudia
    Lovasz, Barbara D.
    Golovics, Petra A.
    Gecse, Krisztina B.
    Szalay, Balazs
    Molnar, Tamas
    Lakatos, Peter L.
    BMC GASTROENTEROLOGY, 2017, 17
  • [4] Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
    Kurti, Z.
    Rutka, M.
    Vegh, Z.
    Gonczi, L.
    Farkas, K.
    Lovasz, B. D.
    Gecse, K. B.
    Golovics, A.
    Szalay, B.
    Molnar, T.
    Lakatos, P. L.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S286 - S286
  • [5] Therapeutic Drug Monitoring of Adalimumab in Patients With Inflammatory Bowel Disease
    El-Matary, Wael
    CROHNS & COLITIS 360, 2019, 1 (03)
  • [6] ASSESSMENT OF THE USE OF THERAPEUTIC DRUG MONITORING OF ADALIMUMAB ON MAINTENANCE THERAPY IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Chavannes, Mallory
    Gervais, France
    Verreault, Alexandra
    Deslandres, Colette
    Jantchou, Prevost
    GASTROENTEROLOGY, 2017, 152 (05) : S394 - S394
  • [7] Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
    Papamichael, Konstantinos
    Clarke, William T.
    Vande Casteele, Niels
    Germansky, Katharine A.
    Feuerstein, Joseph D.
    Melmed, Gil Y.
    Siegel, Corey A.
    Irving, Peter M.
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 839 - +
  • [8] Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel disease
    Chavannes, M.
    Gervais, F.
    Verreault, A.
    Deslandres, C.
    Jantchou, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S255 - S256
  • [9] Experience with therapeutic drug monitoring on adalimumab in paediatric inflammatory bowel disease (pIBD)
    Sider, S.
    Cococcioni, L.
    ElZein, A.
    Chadokufa, S.
    Buckingham, R.
    Shah, N.
    Ocholi, A.
    Borrelli, O.
    Kiparissi, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S566 - S566
  • [10] Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease
    Steenholdt, Casper
    Lorentsen, Ruben Due
    Petersen, Pernille Norgaard
    Widigson, Ella S. K.
    Kloft, Charlotte
    Klaasen, Rolf Anton
    Brynskov, Jorn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1088 - 1098
12345